Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants.

ABSTRACT:

Background

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants has challenged the effectiveness of current therapeutic regimens. Here, we aimed to develop a potent SARS-CoV-2 antibody with broad neutralizing effect by screening a scFv library with the spike protein receptor-binding domain (RBD) via phage display.

Methods

SKAI-DS84 was identified through phage display, and we performed pseudovirus neutralization assays, authentic virus neutralization assays, and in vivo neutralization efficacy evaluations. Furthermore, surface plasmon resonance (SPR) analysis was conducted to assess the physical characteristics of the antibody, including binding kinetics and measure its affinity for variant RBDs.

Results

The selected clones were conve

SUBMITTER: Ko HL 

PROVIDER: S-EPMC10693169 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature